Total Payments
$35,069
2024 Payments
$3,108
Companies
33
Transactions
140
Medicare Patients
106
Medicare Billing
$9,456
Payment Breakdown by Category
Travel$7,376 (21.0%)
Other$7,182 (20.5%)
Consulting$7,061 (20.1%)
Food & Beverage$6,943 (19.8%)
Research$6,507 (18.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $7,376 | 23 | 21.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,182 | 4 | 20.5% |
| Consulting Fee | $7,061 | 5 | 20.1% |
| Food and Beverage | $6,943 | 96 | 19.8% |
| Unspecified | $6,507 | 12 | 18.6% |
Payments by Type
General
$28,562
128 transactions
Research
$6,507
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $7,977 | 5 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $4,865 | 5 | $0 (2024) |
| Roche TCRC, Inc. | $4,062 | 8 | $0 (2020) |
| Allergan Inc. | $3,730 | 20 | $0 (2019) |
| PFIZER INC. | $3,200 | 1 | $0 (2017) |
| Regeneron Pharmaceuticals, Inc. | $2,502 | 13 | $0 (2019) |
| Genentech, Inc. | $2,381 | 22 | $0 (2023) |
| Kyowa Kirin, Inc. | $1,810 | 9 | $0 (2024) |
| Hoffmann-La Roche Limited | $1,462 | 5 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $1,293 | 23 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,108 | 12 | Kyowa Kirin, Inc. ($1,810) |
| 2023 | $2,099 | 6 | Boehringer Ingelheim International GmbH ($1,625) |
| 2022 | $5,131 | 6 | Boehringer Ingelheim International GmbH ($2,590) |
| 2021 | $418.38 | 5 | Heidelberg Engineering, Inc. ($184.27) |
| 2020 | $3,934 | 8 | Roche TCRC, Inc. ($1,968) |
| 2019 | $7,775 | 35 | F. Hoffmann-La Roche AG ($3,101) |
| 2018 | $1,081 | 18 | Genentech, Inc. ($233.45) |
| 2017 | $11,523 | 50 | Allergan Inc. ($3,584) |
All Payment Transactions
140 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/11/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 07/01/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $630.00 | General |
| 05/07/2024 | Kyowa Kirin, Inc. | — | Travel and Lodging | Cash or cash equivalent | $357.60 | General |
| 04/27/2024 | Kyowa Kirin, Inc. | — | Travel and Lodging | In-kind items and services | $266.09 | General |
| 04/27/2024 | Kyowa Kirin, Inc. | — | Food and Beverage | In-kind items and services | $104.70 | General |
| 04/27/2024 | Kyowa Kirin, Inc. | — | Food and Beverage | In-kind items and services | $73.91 | General |
| 04/27/2024 | Kyowa Kirin, Inc. | — | Food and Beverage | In-kind items and services | $46.29 | General |
| 04/27/2024 | Kyowa Kirin, Inc. | — | Food and Beverage | In-kind items and services | $40.65 | General |
| 04/26/2024 | Kyowa Kirin, Inc. | — | Travel and Lodging | In-kind items and services | $382.62 | General |
| 04/26/2024 | Kyowa Kirin, Inc. | — | Travel and Lodging | In-kind items and services | $338.20 | General |
| 04/26/2024 | Kyowa Kirin, Inc. | — | Food and Beverage | In-kind items and services | $199.96 | General |
| 03/14/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 08/07/2023 | BIOTISSUE HOLDINGS, INC. | PROKERA (Device), AMNIOGRAFT | Food and Beverage | In-kind items and services | $123.64 | General |
| Category: HUMAN TISSUE PRODUCTS | ||||||
| 04/23/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $44.00 | General |
| 04/22/2023 | Genentech, Inc. | Lucentis (Biological), Susvimo, Vabysmo | Food and Beverage | In-kind items and services | $145.92 | General |
| Category: Ophthalmology | ||||||
| 04/22/2023 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Food and Beverage | In-kind items and services | $144.96 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 02/16/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| 02/07/2023 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 12/31/2022 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $2,478.00 | Research |
| Study: PDS PHASE 3 ARCHWAY • Category: Ophthalmology | ||||||
| 10/21/2022 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,656.30 | General |
| 10/02/2022 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $30.56 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/30/2022 | Genentech, Inc. | Lucentis (Biological), SUSVIMO, VABYSMO | Food and Beverage | In-kind items and services | $31.64 | General |
| Category: Ophthalmology | ||||||
| 05/03/2022 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $635.00 | General |
| 01/07/2022 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $299.00 | General |
| 12/30/2021 | Heidelberg Engineering, Inc. | Spectralis (Device) | Food and Beverage | Cash or cash equivalent | $184.27 | General |
| Category: Ophthalmology Imaging Equipment | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PDS PHASE 3 ARCHWAY | F. Hoffmann-La Roche AG | $2,478 | 1 |
| A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY | Regeneron Pharmaceuticals, Inc. | $2,260 | 10 |
| A MULTIPLE-CENTER, MULTIPLE-DOSE AND REGIMEN, RANDOMIZED, ACTIVE COMPARATOR CONTROLLED, DOUBLE-MASKED, PARALLEL GROUP, 36 WEEK STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF RO6867461 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE RELATED MACULAR DEGENERATION | F. Hoffmann-La Roche AG | $1,768 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 5 | 106 | 147 | $27,240 | $9,456 |
Total Patients
106
Total Services
147
Medicare Billing
$9,456
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 28 | 36 | $6,850 | $3,632 | 53.0% |
| 67028 | Injection of drug into eye | Office | 2021 | 11 | 23 | $5,600 | $2,260 | 40.4% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 36 | 51 | $10,500 | $1,476 | 14.1% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 12 | 15 | $2,550 | $1,443 | 56.6% |
| 92250 | Photography of the retina | Office | 2021 | 19 | 22 | $1,740 | $644.49 | 37.0% |
About Dr. Brian Berger, MD
Dr. Brian Berger, MD is a Ophthalmology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1649257312.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Berger, MD has received a total of $35,069 in payments from pharmaceutical and medical device companies, with $3,108 received in 2024. These payments were reported across 140 transactions from 33 companies. The most common payment nature is "Travel and Lodging" ($7,376).
As a Medicare-enrolled provider, Berger has provided services to 106 Medicare beneficiaries, totaling 147 services with total Medicare billing of $9,456. Data is available for 1 year (2021–2021), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Austin, TX
- Active Since 12/23/2005
- Last Updated 02/09/2021
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1649257312
Products in Payments
- Non-Covered Product (Drug) $11,515
- OZURDEX (Drug) $3,730
- Lucentis (Biological) $3,662
- EYLEA AFLIBERCEPT INJECTION (Biological) $2,464
- BEOVU (Drug) $949.08
- Spectralis (Device) $184.27
- YUTIQ (Drug) $160.32
- CyPass (Device) $125.52
- Bromsite (Drug) $123.70
- PROKERA (Device) $123.64
- Prokera (Device) $122.35
- XIIDRA (Drug) $121.85
- LUXTURNA (Biological) $109.76
- ACTHAR (Biological) $103.93
- Rhopressa (Drug) $101.95
- PANORAMIC OPHTHALMOSCOPE (Device) $98.67
- SIMBRINZA (Biological) $86.20
- P200DTx (Device) $83.33
- EYLEA (Biological) $62.79
- XR (Device) $43.69
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Austin
Vikram Durairaj, Md, MD
Ophthalmology — Payments: $516,103
Ophthalmology $516,103
Dr. Sheila Barbarino, M.d, M.D
Ophthalmology — Payments: $236,894
Ophthalmology $236,894
Dr. Thomas Walters, Md, MD
Ophthalmology — Payments: $217,539
Ophthalmology $217,539
Chirag Jhaveri, M.d, M.D
Ophthalmology — Payments: $211,408
Ophthalmology $211,408
Dr. Steven Dell, M.d, M.D
Ophthalmology — Payments: $177,840
Ophthalmology $177,840
Dr. Aaron Roller, M.d, M.D
Ophthalmology — Payments: $154,063
Ophthalmology $154,063